Vor Biopharma (NASDAQ:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 22,006 Shares

Key Points

• Reprogrammed Interchange LLC, a major shareholder of Vor Biopharma, sold a total of 22,006 shares at an average price of $32.44, amounting to approximately $713,874, leading to a 1.65% decrease in their ownership stake.
• Vor Biopharma's stock price has declined by 1.9% to $30.22, with a notable fall from a one-year high of $65.80.
• The company reported a significant earnings miss with a loss of $43.60 per share for the last quarter, compared to the consensus estimate of a loss of $11.40.

Vor Biopharma Inc. (NASDAQ:VOR - Get Free Report) major shareholder Reprogrammed Interchange Llc sold 22,006 shares of the business's stock in a transaction on Monday, October 13th. The shares were sold at an average price of $32.44, for a total transaction of $713,874.64. Following the completion of the transaction, the insider directly owned 1,311,786 shares of the company's stock, valued at $42,554,337.84. This trade represents a 1.65% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Reprogrammed Interchange Llc also recently made the following trade(s):

• On Tuesday, October 14th, Reprogrammed Interchange Llc sold 33,668 shares of Vor Biopharma stock. The stock was sold at an average price of $30.32, for a total value of $1,020,813.76.
• On Friday, October 10th, Reprogrammed Interchange Llc sold 40,983 shares of Vor Biopharma stock. The stock was sold at an average price of $30.97, for a total value of $1,269,243.51.
• On Thursday, October 9th, Reprogrammed Interchange Llc sold 48,884 shares of Vor Biopharma stock. The stock was sold at an average price of $32.07, for a total value of $1,567,709.88.
• On Wednesday, October 8th, Reprogrammed Interchange Llc sold 75,262 shares of Vor Biopharma stock. The stock was sold at an average price of $33.87, for a total value of $2,549,123.94.
• On Tuesday, October 7th, Reprogrammed Interchange Llc sold 27,624 shares of Vor Biopharma stock. The stock was sold at an average price of $33.84, for a total value of $934,796.16.
• On Monday, October 6th, Reprogrammed Interchange Llc sold 70,763 shares of Vor Biopharma stock. The shares were sold at an average price of $37.01, for a total value of $2,618,938.63.
• On Friday, October 3rd, Reprogrammed Interchange Llc sold 7,901 shares of Vor Biopharma stock. The shares were sold at an average price of $37.83, for a total value of $298,894.83.
• On Thursday, October 2nd, Reprogrammed Interchange Llc sold 32,451 shares of Vor Biopharma stock. The shares were sold at an average price of $39.83, for a total value of $1,292,523.33.
• On Wednesday, October 1st, Reprogrammed Interchange Llc sold 1,400 shares of Vor Biopharma stock. The shares were sold at an average price of $39.19, for a total value of $54,866.00.
• On Tuesday, September 16th, Reprogrammed Interchange Llc sold 447,278 shares of Vor Biopharma stock. The shares were sold at an average price of $1.54, for a total value of $688,808.12.

Vor Biopharma Stock Down 1.9%

Shares of NASDAQ VOR traded down $0.59 during mid-day trading on Wednesday, hitting $30.22. The company had a trading volume of 724,134 shares, compared to its average volume of 393,854. The company has a market cap of $207.01 million, a P/E ratio of -0.11 and a beta of 2.07. The company has a 50-day moving average price of $37.28. Vor Biopharma Inc. has a one year low of $2.62 and a one year high of $65.80.

Vor Biopharma (NASDAQ:VOR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($43.60) earnings per share for the quarter, missing the consensus estimate of ($11.40) by ($32.20).

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on VOR shares. Zacks Research cut Vor Biopharma from a "hold" rating to a "strong sell" rating in a report on Monday. Wall Street Zen cut Vor Biopharma to a "strong sell" rating in a research report on Saturday, June 28th. Wedbush reissued an "outperform" rating on shares of Vor Biopharma in a report on Thursday, June 26th. Weiss Ratings reissued a "sell (d-)" rating on shares of Vor Biopharma in a report on Wednesday, October 8th. Finally, HC Wainwright reissued a "buy" rating and issued a $60.00 target price on shares of Vor Biopharma in a report on Thursday, August 14th. Five research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Vor Biopharma presently has a consensus rating of "Hold" and a consensus target price of $77.83.

Institutional Investors Weigh In On Vor Biopharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. Money Concepts Capital Corp raised its holdings in Vor Biopharma by 106.1% during the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock worth $37,000 after purchasing an additional 26,535 shares during the last quarter. XTX Topco Ltd bought a new position in Vor Biopharma during the 2nd quarter worth approximately $66,000. Goldman Sachs Group Inc. boosted its position in Vor Biopharma by 218.2% during the first quarter. Goldman Sachs Group Inc. now owns 84,945 shares of the company's stock valued at $61,000 after acquiring an additional 58,247 shares during the last quarter. OMERS ADMINISTRATION Corp bought a new stake in Vor Biopharma during the first quarter valued at $100,000. Finally, Jane Street Group LLC bought a new stake in Vor Biopharma during the first quarter valued at $140,000. Institutional investors and hedge funds own 97.29% of the company's stock.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.